Arbutus Biopharma Corp (ABUS) — 10-Q Filings
All 10-Q filings from Arbutus Biopharma Corp. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Arbutus Narrows Losses by 48% on Soaring Revenue, Cost Cuts
— Nov 13, 2025 Risk: medium
Arbutus Biopharma Corp (ABUS) reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $29.7 million from $57.4 -
Arbutus Biopharma Q2 Loss Widens Amid Rising R&D Costs
— Aug 6, 2025 Risk: high
Arbutus Biopharma Corp reported a net loss of $25.2 million for the three months ended June 30, 2025, a significant increase from the net loss of $19.8 million - 10-Q Filing — May 14, 2025
-
Arbutus Biopharma Reports Q3 2024 Results
— Nov 6, 2024 Risk: medium
Arbutus Biopharma Corp. reported its financial results for the quarter ended September 30, 2024. The company's revenue from collaboration and contracts for the -
Arbutus Biopharma Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Arbutus Biopharma Corp. filed a 10-Q for the period ending June 30, 2024. The company, formerly Tekmira Pharmaceuticals Corp., reported financial results for th -
Arbutus Biopharma Corp Files 10-Q for Period Ending March 31, 2024
— May 2, 2024 Risk: low
Arbutus Biopharma Corp (ABUS) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Arbutus Biopharma Corp filed a 10-Q report for the period ending Marc
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX